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Small Intestinal Bacterial Overgrowth and Lactose  
Intolerance Contribute to Irritable Bowel Syndrome 
Symptomatology in Pakistan
Javed Yakoob, Zaigham Abbas, Rustam Khan, Saeed Hamid, Safia Awan, Wasim Jafri
ABSTRACT
Background /Aim: The symptoms of irritable bowel syndrome resemble those of small intestinal bacterial 
overgrowth (SIBO). The aim of this study was to determine the frequency of SIBO and lactose intolerance 
(LI) occurrence in patients with diarrhea-predominant irritable bowel syndrome (IBS-D) according to Rome 
III criteria. Patients and Methods: In this retrospective case-control study, patients over 18 years of age with 
altered bowel habit, bloating, and patients who had lactose Hydrogen breath test (H2BT) done were included. 
The “cases” were defined as patients who fulfill Rome III criteria for IBS-D, while “controls” were those 
having chronic nonspecific diarrhea (CNSD) who did not fulfill Rome III criteria for IBS-D. Demographic 
data, predominant bowel habit pattern, concurrent use of medications, etc., were noted. Results: Patients 
with IBS-D were 119 (51%) with a mean age of 35 ± 13 years, while those with CNSD were 115 (49%) with 
mean age 36 ± 15 years. Patients in both IBS-D and CNSD were comparable in gender,  with male 87 (74%) 
and female 77 (64%). SIBO was documented by lactose H2BT in 32/234 (14%) cases. It was positive in 22/119 
(19%) cases with IBS-D, while 10/115 (9%) cases had CNSD (P = 0.03). LI was positive in 43/234 (18%) 
cases. Of these, 25/119 (21%) cases had IBS-D and 18/115 (16%) cases had CNSD (P = 0.29). Conclusion: 
SIBO was seen in a significant number of our patients with IBS-D. There was no significant age or gender 
difference in patients with or without SIBO.
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Irritable bowel syndrome (IBS) is the most commonly 
diagnosed chronic functional gastrointestinal disorder 
worldwide including Asia.[1,2] IBS affects females 
approximately twice as often as males and is most frequently 
diagnosed in individuals between the ages of 30 and 50 
years.[1,2] However, there is a lack of female dominance in 
Asian studies.[3] Symptoms of IBS can substantially impact 
patients’ quality of life, and the effect of IBS on physical and 
psychological health can negatively impact the workplace.[4-6] 
The economic burden of IBS is substantial and includes 
direct physicians’ costs as well as indirect costs in terms of 
employee absenteeism. IBS is characterized by abdominal 
discomfort associated with altered bowel habits including 
constipation, diarrhea, or alternating periods of constipation 
and diarrhea.
An emerging hypothesis suggests that small intestinal 
bacterial overgrowth (SIBO) may contribute to IBS 
pathophysiology.[7] SIBO is a condition characterized by 
abnormally high bacterial count (≥105 colony-forming units/
ml) in the proximal small intestine, resembling distribution 
of bacteria normally found in the colon.[8,9] Symptoms of 
SIBO include abdominal pain, bloating, flatulence, and 
diarrhea, similar to those observed in patients with IBS.[10,11] 
SIBO was detected in 17 to 84% of patients who met Rome 
I or Rome II[12-16] criteria for IBS using Hydrogen breath 
testing (H2BT) with glucose or lactulose. Furthermore, 
treatment with antibiotics can reduce or eradicate SIBO[16-21] 
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and improve symptoms of IBS[22,23] which supports the 
role of SIBO in IBS. As diagnosis of IBS is based on a 
combination of symptoms that are also common in patients 
with malabsorption disorders, it is possible that some of 
these patients may be misdiagnosed as IBS, particularly 
if specific tests are not performed.[7] This was supported 
by the reports of diagnosis of celiac disease in patients 
presenting as IBS.[19-21] As H2BT is simpler to administer, 
is more cost-effective, and does not expose the patient to 
radiation, it has become the noninvasive gold standard in 
the diagnosis of SIBO. Previously, SIBO in IBS was shown 
to be associated with positive lactose H2BT.
[15] In a study of 
98 consecutive IBS patients, a positive lactulose breath test 
was found in 64 of 98 (65%) subjects; these SIBO patients 
showed a significantly higher prevalence of positivity to the 
lactose breath test (P<0.05).[15] Clinical studies evaluating 
characteristics associated with SIBO in patients with IBS-
diarrhea (IBS-D) according to Rome III criteria are lacking. 
Therefore, the purpose of this study was to determine the 
frequency of SIBO and lactose intolerance (LI) occurrence 
in patients with IBS-D according to Rome III criteria and 
determine the predictors of SIBO in these patients.
PATIENTS AND METHODS
Patients
In this retrospective case-controlled study, the medical 
records of patients over 18 years of age who attended 
gastroenterology clinic supervised by the investigators 
at the University Hospital with altered bowel habit and 
bloating, were included. They had lactose H2BT done 
between January 2007 and October 2010. The Ethics 
Review Committee at the University approved the study. 
The “cases” had, over the past three months or more, at 
least three bowel movements per day described as loose 
or watery stools associated with urgency, and fulfilled the 
Rome III criteria for IBS-D,[2] while “controls” were those 
having chronic nonspecific diarrhea (CNSD) defined as 
abdominal pain or discomfort associated with intermittent 
diarrhea with more than 3 stools a day for at least 4 weeks 
and less than 12 weeks and did not fulfill Rome III criteria 
for IBS-D.[24] Demographic data, predominant bowel habit 
pattern, and concurrent use of medications were noted. 
These patients underwent thorough history, physical 
examination, complete blood count, serum creatinine, 
electrolytes, and stool microscopy. All the patients had 
colonoscopy with rectal biopsy to exclude inflammatory 
bowel disease and microscopic colitis. Exclusion criteria 
were concurrent use of opiates analgesics, prokinetic 
drugs, and PPI, having infection with Giardia lamblia, 
Entameba histolytica, Blastocystis hominis, positive 
serology for celiac disease as determined by tissue 
transglutaminase antibody-IgA and transglutaminase 
antibody-IgG and abnormal thyroid activity as suggested 
by serum thyroxin and thyroid-stimulating hormone level. 
Patients with predisposing conditions for SIBO, e.g., prior 
small intestinal surgery, scleroderma, diabetes mellitus, 
liver cirrhosis, forms of autonomic neuropathy, history 
of peptic ulcer and therapy with H2 antagonists/PPIs 
during the preceding 8 weeks, hypothyroidism, intestinal 
pseudo-obstruction, colonoscopy within a week before 
H2BT, and drugs known to interfere with gastrointestinal 
motility, e.g., anticholinergics and antidepressants were 
also excluded.
Hydrogen breath test
All patients underwent a lactose H2BT at the beginning of 
the study. Immediately before the H2BT, patients used a 
mouthwash containing 40 ml of 1% chlorhexidine. The H2BT 
was done with patient fasting overnight for 12 hours. Patients 
were asked to refrain from smoking after the last meal till 
the end of the test and from exercise 30 minutes before and 
during the test. Antibiotics were stopped 4 weeks before 
administering the SIBO breath test. Patients also avoided 
laxatives, stool softeners, or stool bulking agents one week 
prior to the test. Food with high fiber content, e.g., beans, 
pasta, meats, fiber or bran cereals, cola drinks, butter, or 
margarine, was avoided 24 hours prior to the test. Samples 
of expired air were collected. Five samples were collected 
including one fasting sample (0 minute) after the dose of 
50 g lactose for adult, and four samples at 30, 60, 90, and 120 
minutes interval. Expiratory breath samples obtained were 
analyzed immediately after collection, using a commercial 
device (GaSampler; QuinTron Instrument Company, 
Milwaukee, Wisconsin). Gas chromatography (Model DP; 
QuinTron Instrument Company, Milwaukee, Wisconsin) was 
employed to measure the concentration in parts per million 
(ppm) of hydrogen in the air. The diagnostic criteria for a 
positive SIBO was a rise above baseline of 20 ppm in 30 or 
60-minute breath sample, while isolated positive breath test 
at 90 or 120-minute samples corresponding to the passage of 
lactose into the colon was taken as LI rather than SIBO.[23,24] 
Definitions of normal and abnormal results of breath tests are 
variable and there is a lack of generally accepted definitions. 
The sensitivity and specificity of the lactulose H2BT in 
detecting SIBO has been reported to be only 68% and 44%, 
respectively.[25] However, sensitivity in general is acceptable, 
because of the low specificity for diagnosing SIBO compared 
with jejunal cultures.[26]
Sample size
The software EPI Info was utilised for sample size 
estimation. Assuming a 30% prevalence of SIBO in IBS-D 
and 8% in CNSD,[27] a two-sided alpha of 0.05 and odds 
ratio of 2 with an 80% power to detect a difference, the 
required sample size for this objective was 115 for the cases 
and 115 for control.
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Statistical method
Results were expressed as mean + standard deviation for 
continuous variables (e.g., age) and number (percentage) for 
categorical data (e.g., gender, diarrhea, etc.). Comparison 
of IBS-D patients and CNSD patients with other covariates 
like age, gender, hydrogen test, hemoglobin, and serology of 
celiac disease was done by using the independent sample 
t-test, Pearson Chi-square test, and Fisher Exact test where 
appropriate. The patients were further divided into SIBO 
positive and SIBO negative and a comparison was done 
with other covariates. A P value of <0.05 was considered 
as statistically significant. All P values were two sided. 
Statistical interpretation of data was performed by using 
the computerized software program SPSS version 17.0.
RESULTS
Patients with IBS-D (119, 51%) had a mean age of 35 ± 13 
years and male : female ratio was 88 : 31, while those with 
CNSD (115, 49%) were 36 ± 15 years and male : female ratio 
of 77 : 38 [Table 1]. Patients with IBS-D were comparable 
in age with that of CNSD (mean age, 35 ± 13 years vs 36 ± 
15 years, P = 0.38). Patients in both IBS-D and CNSD were 
also comparable in gender with more often male 88 (74%) 
and female 77 (67%) [Table 1].
None of the patients in the two groups got excluded due to 
the diagnosis of celiac disease, thyroid diseases, or presence of 
gastrointestinal infection with Giardia lamblia, Blastocystis 
hominis, etc. Serology for celiac disease anti-TTG IgA and 
IgG and colonic biopsies were reported normal.
Comparison of symptoms in diarrhea-predominant 
irritable bowel syndrome and Chronic diarrhea
Patients in both groups had chronic diarrhea [Table 1]. 
Abdominal pain was significant in IBS-D (71, 60%) compared 
with chronic diarrhea (54, 47%) (P = 0.05) [Table 1]. 
Bloating was equally present in both,  patients with chronic 
diarrhea (37, 32%) (P = 0.10).
Association of age and gender with small intestinal 
bacterial overgrowth
SIBO was positive in 32/234 (14%) cases. The mean age of 
patients with positive SIBO was 32 ± 14 years (age range, 18-
61 years) and 36 ± 14 years (age range, 18-80 years) in those 
negative for SIBO [Table 2]. Of the 32 patients with positive 
SIBO, 22 (69%) were males, while 10 (31%) were females.
Comparison of small intestinal bacterial overgrowth 
in groups
SIBO was positive in 22/119 (19%) with IBS-D, while 10/115 
(9%) had CNSD (P = 0.03) [Table 2]. Of 22 patients with 
SIBO in IBS-D, 16/22 (73%) were males and 6/22 (27%) were 
females, while in those with CNSD, 6/10 (60%) were males 
and 4/10 (40%) were females (P = 0.81) [Tables 1 and 2].
Table 1: Demographic, clinical, and laboratory 
parameters of IBS-D patients and chronic nonspecific 
diarrhea
Parameters IBS
n=119
CNSD
n=115
P value
Age
Mean ± SD (yr) 35 ± 13 36 ± 15 0.38
Range 18-74 18-80
Sex
Male:Female ratio 88:31 77:38 0.24
Diagnosis
Small intestinal bacterial overgrowth
Positive 22 (19) 10 (9) 0.03*
Negative 97 (81) 105 (91)
Lactose intolerance
Positive 25 (21) 18 (15) 0.29
Negative 94 (79) 97 (85)
Clinical feature
Abdominal pain
Positive 71 (60) 54 (47) 0.05
Negative 48 (40) 61 (53)
Bloating
Positive 50 (42) 37 (32) 0.12
Negative 69 (58) 78 (68)
Chronic diarrhea
Positive 114 (96) 104 (90) 0.10
Negative 5 (4) 11 (10)
*n (%) = number and percentage; *A P value of <0.05 was considered as 
statistically significant
Table 2: Comparison of patients with small intestinal bacterial overgrowth and lactose intolerance
Parameters SIBO Lactose Intolerance
Positive
n=32 (14)
Negative 
n=202 (86)
P value Positive
n=43 (18)
Negative
n=191 (82)
P value
Age
Mean ± SD (yr) 33 ± 14 36 ± 14 0.24 32 ± 12 36 ± 14 0.23
Sex
Male: Female ratio 22:10 143:59 0.81 23:20 142:49 0.007*
*n (%) = number and percentage; *A P value of <0.05 was considered as statistically significant
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Association of age and gender with lactose 
intolerance
LI was present in 25/119 (21%) cases with IBS-D compared 
with 18/115 (16%) cases with CNSD (P = 0.29). The mean 
age of IBS-D patients with positive LI was 32 ± 13 years 
(age range, 18-62 years), while those with CNSD was 36 ± 
14 years (age range, 18-80 years) (P = 0.23) [Table 2]. Of 
the 43 patients with positive LI, 23 (54%) were males and 
20 (46%) were females (P = 0.007).
DISCUSSION
Previous studies reported contradictory results about the 
prevalence of SIBO in patients with IBS.[7,12,20,28-33] The 
variation in prevalence of SIBO in different studies could be 
attributed to their geographical location, studied population, 
criteria used for IBS diagnosis, and method used for the 
diagnosis of SIBO.
The present study showed that SIBO was more prevalent 
in patients with IBS-D (19%) compared with those with 
CNSD (9%). Patients with IBS-D and CNSD had similar 
mean age [Table 1]. SIBO was seen more commonly in male 
patients compared with female; however, in both IBS-D and 
CNSD, there was a preponderance of male patients. This is 
in keeping with previous observation that in Asian countries 
men are more likely to report symptoms of IBS as compared 
to women.[3] This is due to social attributes of the Asian 
society. LI was not more common in patients with IBS-D but 
patients were comparatively more of male gender [Tables 1 
and 2]. We found that individuals with IBS-D had LI, in the 
absence of apparent complaints of lactose malabsorption.
The 19% frequency of SIBO in IBS-D patients in this study is 
similar to the one reported from India.[34] It is, however, much 
less than SIBO incidence of 78% reported in one study from 
USA.[16] Such a high frequency of SIBO was not reported in 
any subsequent study no matter which criteria was used for 
the diagnosis of IBS.[30-33] The unusually high frequency of 
SIBO was probably related to the criteria used to diagnose 
SIBO[16] which presumed that a rise in breath hydrogen 
20 ppm above basal levels within 90 minutes after ingestion 
of test meal was diagnostic of SIBO.[16] This criterion 
presumed that mouth-to-cecum transit time was always 
greater than 90 minutes, so that a peak in breath hydrogen 
within 90 minutes after test meal ingestion must be due to 
bacterial fermentation in the small bowel. Mouth-to-cecum 
transit times in Asian population have been reported to be 
shorter than 90 minutes.[35,36] The median mouth-to-cecum 
transit time in healthy Indian subjects was 65 minutes with 
a range of 40 to 110 minutes.[37] Therefore, in the present 
study, the diagnostic criteria for a positive SIBO were a rise 
above baseline of 20 ppm up to the 60-minute breath sample 
collection. In this study, we used Rome III criteria for the 
diagnosis of IBS-D, as a recent study determined the degree 
of agreement between Rome III and Rome II criteria in 
diagnosing IBS, and reported that the severity of bowel habit 
did not agree among the four subtypes (P<0.005).[38] The 
limitations of this study include being retrospective and lack 
of lactose H2BT in healthy controls. However, it is interesting 
that SIBO was observed in comparatively young IBS-D 
patients, rather than in elderly patients, who are more likely 
to experience slow intestinal transit. Also, LI was frequent in 
male patients. These patients with SIBO were treated with 
ciprofloxacin 250 mg twice a day and folic acid 5 mg a day 
for 6 weeks and all patients experienced symptomatic relief.
The implications of this study are that in IBS-D, symptoms 
may be due to SIBO or LI that may need to be ruled 
out. Treatment with antibiotics may follow resolution of 
symptoms in patients with SIBO. However, revision of 
diagnosis of IBS-D did not follow in our patients with 
IBS-D as it has been reported in a previous study.[16] This 
may be attributed to a small number of patients in our 
study and need to be looked at in a prospective study with 
a larger sample size. A period of dairy product avoidance 
and/or lactose supplementation requesting a test for lactose 
malabsorption will be required for the documentation of 
LI. In conclusion, SIBO was seen in a significant number 
of our patients with IBS-D according to Rome III criteria. 
These patients were young and did not exhibit gender 
predisposition.
REFERENCES
1. American College of Gastroenterology Functional Gastrointestinal 
Disorders Task Force. Evidence-based position statement on the 
management of irritable bowel syndrome in North America. Am J 
Gastroenterol 2002;97(11 suppl):S1-5.
2. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical 
review on irritable bowel syndrome. Gastroenterology 2002;123:2108-31.
3. Jafri W, Yakoob J, Jafri N, Islam M, Ali QM. Irritable bowel syndrome 
and health seeking behavior in different communities of Pakistan. J 
Pak Med Assoc 2007;57:285-7.
4. Gralnek IM, Hays RD, Kilbourne A, Naliboff B, Mayer EA. The 
impact of irritable bowel syndrome on health-related quality of 
life. Gastroenterology 2000;119:654-60.
5. Cash B, Sullivan S, Barghout V. Total costs of IBS: Employer and managed 
care perspective. Am J Manag Care 2005;11(1 suppl):S7-16.
6. Dean BB, Aguilar D, Barghout V, Kahler KH, Frech F, Groves D, et al. 
Impairment in work productivity and health-related quality of life in 
patients with IBS. Am J Manag Care 2005;11(1 suppl):S17-26.
7. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson 
WG, et al. U.S. householder survey of functional gastrointestinal 
disorders. Prevalence, sociodemography, and health impact. Dig Dis 
Sci 1993;38:1569-80.
8. Hulisz D. The burden of illness of irritable bowel syndrome: Current 
challenges and hope for the future. J Manag Care Pharm 2004;10:299-309.
9. Lin HC. Small intestinal bacterial overgrowth: A framework for 
understanding irritable bowel syndrome. JAMA 2004;292:852-8.
[Downloaded free from http://www.saudijgastro.com on Wednesday, April 18, 2018, IP: 221.132.113.70]
Small intestinal bacterial overgrowth in IBS-D
375
Volume 17, Number 6
Dhul Hijjah 1432H 
November 2011
The Saudi Journal of
Gastroenterology
10. Husebye E. The pathogenesis of gastrointestinal bacterial 
overgrowth. Chemotherapy 2005;51(suppl 1):1-22.
11. Simrén M, Stotzer PO. Use and abuse of hydrogen breath 
tests. Gut 2006;55:297-303. 
12. Di Stefano M, Corazza GR. Treatment of small intestine bacterial 
overgrowth and related symptoms by rifaximin. Chemotherapy 
2005;51(suppl 1):103-9. 
13. Singh VV, Toskes PP. Small bowel bacterial overgrowth: Presentation, 
diagnosis, and treatment. Curr Treat Options Gastroenterol 2004;7:19-28. 
14. Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, 
Cammarota G, et al. Hydrogen glucose breath test to detect small 
intestinal bacterial overgrowth: A prevalence case-control study in 
irritable bowel syndrome. Aliment Pharmacol Ther 2005;22:1157-60. 
15. Nucera G, Gabrielli M, Lupascu A, Lauritano EC, Santoliquido A, 
Cremonini F, et al. Abnormal breath tests to lactose, fructose and 
sorbitol in irritable bowel syndrome may be explained by small intestinal 
bacterial overgrowth. Aliment Pharmacol Ther 2005;21:1391-5. 
16. Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath 
testing correlates with symptom improvement in irritable bowel 
syndrome. a double-blind, randomized, placebo-controlled study. Am 
J Gastroenterol 2003;98:412-9. 
17. Walters B, Vanner SJ. Detection of bacterial overgrowth in IBS using 
the lactulose H2 breath test: Comparison with 14C-d-xylose and healthy 
controls. Am J Gastroenterol 2005;100:1566-70. 
18. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial 
overgrowth reduces symptoms of irritable bowel syndrome. Am J 
Gastroenterol 2000;95:3503-6. 
19. Di Stefano M, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Rifaximin 
versus chlortetracycline in the short-term treatment of small intestinal 
bacterial overgrowth. Aliment Pharmacol Ther 2000;14:551-6. 
20. Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza 
GR. Non-absorbable antibiotics for managing intestinal gas production 
and gas-related symptoms. Aliment Pharmacol Ther 2000;14:1001-8. 
21. Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, 
Scarpellini E, et al. Rifaximin dose-finding study for the treatment 
of small intestinal bacterial overgrowth. Aliment Pharmacol 
Ther 2005;22:31-5. 
22. Majewski M, McCallum RW. Results of small intestinal bacterial 
overgrowth testing in irritable bowel syndrome patients: Clinical 
profiles and effects of antibiotic trial. Adv Med Sci 2007;52:139-42. 
23. Majewski M, Reddymasu SC, Sostarich S, Foran P, McCallum RW. Efficacy 
of rifaximin, a nonabsorbed oral antibiotic, in the treatment of small 
intestinal bacterial overgrowth. Am J Med Sci 2007;333:266-70. 
24. Teo M, Chung S, Chitti L, Tran C, Kritas S, Butler R, et al. Small 
bowel bacterial overgrowth is a common cause of chronic diarrhea. 
J Gastroenterol Hepatol 2004;19:904-9.
25. Corazza GR, Menozzi M G, Strocchi A, Rasciti L, Vaira D, Lecchini R, et al. 
The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal 
culture and inadequacy of breath hydrogen testing. Gastroenterology 
1990;98:302-9.
26. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a 
nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable 
bowel syndrome: A randomized trial. Ann Intern Med 2006;145:557-63.
27. Sharara AI, Aoun E, Abdul-Baki H, Mounzer R, Sidani S, Elhajj I. A 
randomized double-blind placebo-controlled trial of rifaximin in 
patients with abdominal bloating and flatulence. Am J Gastroenterol 
2006;101:326-33.
28. Rhodes JM, Middleton P, Jewell DP. The lactulose hydrogen breath 
test as a diagnostic test for small-bowel bacterial overgrowth. Scand 
J Gastroenterol 1979;14:333-6.
29. Kerlin P, Wong L. Breath hydrogen testing in bacterial overgrowth of 
the small intestine. Gastroenterology 1988;95:982-8.
30. Ghoshal UC, Kumar S, Mehrotra M, Lakshmi C, Misra A. Frequency of 
small intestinal bacterial overgrowth in patients with irritable bowel 
syndrome and chronic non-specific diarrhea. J Neurogastroenterol 
Motil 2010;16:40-6.
31. Pimentel M. The prevalence of small intestinal bacterial overgrowth 
in irritable bowel syndrome: IBS vs. healthy controls (not historical 
definitions). Gut 2008;57:1334-5.
32. Vanner S. The small intestinal bacterial overgrowth. Irritable bowel 
syndrome hypothesis: Implications for treatment. Gut 2008;57:1315-21.
33. Rana SV, Sinha SK, Sikander A, Bhasin DK, Singh K. Study of small 
intestinal bacterial overgrowth in North Indian patients with irritable 
bowel syndrome: A case control study. Trop Gastroenterol 2008;29:23-5.
34. Gupta D, Ghoshal UC, Misra A, Choudhuri G, Singh K. Lactose 
intolerance in patients with irritable bowel syndrome from northern 
India: a case-control study. J Gastroenterol Hepatol 2007;22:2261-5.
35. Paik CN, Choi MG, Nam KW. The prevalence of small intestinal bacterial 
overgrowth in Korean patients with irritable bowel syndrome. Korean. 
Neurogastroenterol Motil 2007;13:38-44.
36. Ghoshal UC, Ghoshal U, Ayyagari A, Ranjan P, Krishnani N, Misra A, 
et al. Tropical sprue is associated with contamination of small bowel 
with aerobic bacteria and reversible prolongation of oro-cecal transit 
time. J Gastroenterol Hepatol 2003;18:540-7.
37. Lu CL, Chen CY, Chang FY, Lee SD. Characteristics of small bowel 
motility in patients with irritable bowel syndrome and normal humans: 
An oriental study. Clin Sci (Lond) 1998;95:165-9.
38. Wang AJ, Liao XH, Hu PJ, Liu SC, Xiong LS, Chen MH. A comparison 
between Rome III and Rome II criteria in diagnosing irritable bowel 
syndrome. Chinese J Intern Med 2007;46:644-7.
Source of Support: Nil, Conflict of Interest: None declared.
[Downloaded free from http://www.saudijgastro.com on Wednesday, April 18, 2018, IP: 221.132.113.70]
